Table 4 Atypical antipsychotic AEs reported by physicians as clinically important and/or bothersome
AEs, n (%) | Clinically important (n = 4) | Most clinically important (n = 4) | Most bothersome to patients (n = 4) |
|---|---|---|---|
Metabolic syndrome a | 4 (100) | 4 (100) | n/a |
Weight gain | 4 (100) | 2 (50) | 4 (100) |
Reduced sexual desire or performance | 4 (100) | 1 (25) | 2 (50) |
Neutropenia b | 3 (75) | 3 (75) | 1 (25) |
Hyperglycemia b | 3 (75) | 2 (50) | 0 |
EPS b | 3 (75) | 1 (25) | 2 (50) |
Hyperlipidemia | 3 (75) | 1 (25) | 0 |
Akathisia | 3 (75) | 0 | 2 (50) |
QT prolongation b | 2 (50) | 2 (50) | 0 |
Major medical (seizures) | 2 (50) | 1 (25) | 1 (25) |
Hormonal | 2 (50) | 0 | 2 (50) |
Hypotension | 2 (50) | 0 | 1 (25) |
Cognitive issues | 2 (50) | 0 | 1 (25) |
Major medical (diabetes) b | 1 (25) | 1 (25) | 1 (25) |
Hypertension | 1 (25) | 1 (25) | 0 |
Low energy | 1 (25) | 0 | 1 (25) |
Depressive symptoms | 1 (25) | 0 | 0 |
Flat/restricted affect | 1 (25) | 0 | 0 |
Somnolence/sedation | 1 (25) | 0 | 0 |